TY - JOUR
T1 - Repulsive guidance molecule a (RGMa) induces neuropathological and behavioral changes that closely resemble parkinson’s disease
AU - Korecka, Joanna A
AU - Moloney, Elizabeth B.
AU - Eggers, Ruben
AU - Hobo, Barbara
AU - Scheffer, Sanny
AU - Ras-Verloop, Nienke
AU - Jeroen Pasterkamp, R.
AU - Swaab, Dick F.
AU - Smit, August B
AU - van Kesteren, Ronald E.
AU - Bossers, Koen
AU - Verhaagen, Joost
PY - 2017/9/27
Y1 - 2017/9/27
N2 - Repulsive guidance molecule member a (RGMa) is a membrane-associated or released guidance molecule that is involved in axon guidance, cell patterning, and cell survival. In our previous work, we showed that RGMa is significantly upregulated in the substantia nigra of patients with Parkinson’s disease. Here we demonstrate the expression of RGMa in midbrain human dopaminergic (DA) neurons. To investigate whether RGMa might model aspects of the neuropathology of Parkinson’s disease in mouse, we targeted RGMa to adult midbrain dopaminergic neurons using adeno-associated viral vectors. Overexpression of RGMa resulted in a progressive movement disorder, including motor coordination and imbalance, which is typical for a loss of DA release in the striatum. In line with this, RGMa induced selective degeneration of dopaminergic neurons in the substantia nigra (SN) and affected the integrity of the nigrostriatal system. The degeneration of dopaminergic neurons was accompanied by a strong microglia and astrocyte activation. The behavioral, molecular, and anatomical changes induced by RGMa in mice are remarkably similar to the clinical and neuropathological hallmarks of Parkinson’s disease. Our data indicate that dysregulation of RGMa plays an important role in the pathology of Parkinson’s disease, and antibody-mediated functional interference with RGMa may be a disease modifying treatment option.
AB - Repulsive guidance molecule member a (RGMa) is a membrane-associated or released guidance molecule that is involved in axon guidance, cell patterning, and cell survival. In our previous work, we showed that RGMa is significantly upregulated in the substantia nigra of patients with Parkinson’s disease. Here we demonstrate the expression of RGMa in midbrain human dopaminergic (DA) neurons. To investigate whether RGMa might model aspects of the neuropathology of Parkinson’s disease in mouse, we targeted RGMa to adult midbrain dopaminergic neurons using adeno-associated viral vectors. Overexpression of RGMa resulted in a progressive movement disorder, including motor coordination and imbalance, which is typical for a loss of DA release in the striatum. In line with this, RGMa induced selective degeneration of dopaminergic neurons in the substantia nigra (SN) and affected the integrity of the nigrostriatal system. The degeneration of dopaminergic neurons was accompanied by a strong microglia and astrocyte activation. The behavioral, molecular, and anatomical changes induced by RGMa in mice are remarkably similar to the clinical and neuropathological hallmarks of Parkinson’s disease. Our data indicate that dysregulation of RGMa plays an important role in the pathology of Parkinson’s disease, and antibody-mediated functional interference with RGMa may be a disease modifying treatment option.
KW - AAV-mediated overexpression
KW - Dopamine neuron degeneration
KW - Parkinson’s disease
KW - RGMa
UR - https://www.scopus.com/pages/publications/85030176690
U2 - 10.1523/JNEUROSCI.0084-17.2017
DO - 10.1523/JNEUROSCI.0084-17.2017
M3 - Article
C2 - 28842419
AN - SCOPUS:85030176690
SN - 0270-6474
VL - 37
SP - 9361
EP - 9379
JO - Journal of Neuroscience
JF - Journal of Neuroscience
IS - 39
ER -